Why a U.K. government plan to disclose financial ties between pharma and docs may fall short; Startup launches with $245 million for twice yearly asthma treatment

Taking stock of the drug industry, from the lab to the medicine chest

October 24, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | 'Missed opportunities': Why a U.K. government plan to disclose financial ties between pharma and docs may fall short The U.K. government plans to create a database similar to one in the U.S. that was set up in response to concerns about industry influence. By Ed Silverman STAT+ | Startup launches with $245 million for twice yearly asthma treatment Aiolos Therapeutics was founded by former Genentech employees who stumbled upon an asthma drug being developed by a Chinese company. By Allison DeAngelis Opinion: Insulin is increasingly affordable in the U.S. What about the rest of the world? Insulin prices have started to come down in the U.S. How can we ensure people around the world have the same access? By David Panzirer STAT/AstraZeneca via AP CDC recommends rationing of RSV shot due to shortages In a health alert, the CDC said clinicians should prioritize available doses for babies at highest risk from respiratory syncytial virus. By Helen Branswell AstraZeneca, maker of FluMist, seeks to allow at-home administration of vaccine If AstraZeneca's application is approved by the FDA, the vaccine would be ordered and delivered after consultation with a medical professional. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser